Earnings summaries and quarterly performance for HAEMONETICS.
Executive leadership at HAEMONETICS.
Christopher Simon
Detailed
President and Chief Executive Officer
CEO
FC
Frank Chan
Detailed
Executive Vice President, Chief Operating Officer
JD
James D'Arecca
Detailed
Executive Vice President, Chief Financial Officer
LM
Laurie Miller
Detailed
Senior Vice President, Chief Human Resources Officer
MB
Michelle Basil
Detailed
Executive Vice President, General Counsel
RG
Roy Galvin
Detailed
Executive Vice President, Chief Commercial Officer
Board of directors at HAEMONETICS.
Research analysts who have asked questions during HAEMONETICS earnings calls.
Andrew Cooper
Raymond James
4 questions for HAE
Also covers: AZTA, CDNA, CTKB +12 more
AP
Anthony Petrone
Mizuho Group
4 questions for HAE
Also covers: ADMA, ALC, BSX +22 more
Marie Thibault
BTIG
4 questions for HAE
Also covers: ABT, ARAY, ATRC +15 more
CB
Craig Bijou
Bank of America Securities
3 questions for HAE
Also covers: BLCO, COO, FNA +9 more
Michael Matson
Needham & Company
3 questions for HAE
Also covers: AORT, ATRC, CNMD +22 more
MP
Michael Petusky
Barrington Research
3 questions for HAE
Also covers: ANIK, HSIC, LFCR +8 more
RP
Rohin Patel
JPMorgan Chase & Co.
3 questions for HAE
Also covers: CVRX, INGN, NPCE
DT
David Turkaly
Citizens JMP
2 questions for HAE
Also covers: AXGN, FNA, LNTH +4 more
Joanne Wuensch
Citigroup Inc.
2 questions for HAE
Also covers: ABT, BAX, BDX +18 more
LS
Lawrence Solow
CJS Securities, Inc.
2 questions for HAE
Also covers: BTSG, CDRE, CLH +13 more
Anthony Occhiogrosso
Citigroup Inc.
1 question for HAE
Also covers: IRTC
DR
David Rescott
Baird
1 question for HAE
Also covers: INSP, IRTC, LIVN +7 more
KS
Kristen Stewart
CL King & Associates
1 question for HAE
Also covers: AVNS, CNMD, IART +3 more
LS
Larry Solow
CJS Securities
1 question for HAE
Also covers: ARCB, BTSG, CDRE +14 more
Mike Matson
Needham & Company, LLC
1 question for HAE
Also covers: CNMD, ENOV, ESTA +16 more
Recent press releases and 8-K filings for HAE.
Haemonetics Reports Strong Q3 2026 Results and Raises Full-Year Guidance
HAE
Earnings
Guidance Update
M&A
- Haemonetics reported Q3 2026 revenue of $339 million and adjusted earnings per share of $1.31, contributing to year-to-date revenue of $988 million and adjusted EPS of $3.67.
- The company raised its full-year fiscal 2026 guidance, now expecting total reported revenue to decline by 1%-3% and organic revenue ex-CSL to grow by 8%-10%. Adjusted EPS guidance was updated to $4.90-$5.00 per share.
- Plasma organic growth ex-CSL accelerated to 20% in the quarter, and Blood Management Technologies grew 8%. Interventional Technologies revenue declined 12% in Q3 but is anticipated to return to growth in FY 2027.
- Free cash flow for Q3 was $74 million, bringing the year-to-date total to $165 million, leading to a raised full-year free cash flow guidance of $200-$220 million.
- Subsequent to quarter end, Haemonetics acquired Vivasure for $61 million to enhance its interventional technologies portfolio, with a planned commercial launch of PerQseal Elite in fiscal 2027.
3 hours ago
Haemonetics Reports Strong Q3 2026 Results and Raises Full-Year Guidance
HAE
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Haemonetics reported Q3 2026 revenue of $339 million, bringing year-to-date revenue to $988 million, with organic growth ex-CSL of 8% in the quarter and 10% year-to-date.
- Adjusted earnings per share increased 10% in Q3 to $1.31 and 11% year-to-date to $3.67. The company generated $74 million in free cash flow in Q3, bringing year-to-date free cash flow to $165 million.
- Full-year fiscal 2026 guidance was raised for adjusted EPS to $4.90-$5.00 per share, free cash flow to $200 million-$220 million, reported revenue to a decline of 1%-3%, and organic revenue ex-CSL to 8%-10%.
- Plasma performance accelerated with 20% organic growth ex-CSL in Q3, while Blood Management Technologies delivered solid growth of 8%. Interventional Technologies declined 12% in Q3 but is expected to return to growth in FY 2027.
- Subsequent to quarter end, Haemonetics acquired Vivisure for $61 million to strengthen its interventional technologies portfolio and repurchased approximately 360,000 shares for $25 million.
4 hours ago
HAE Reports Strong Q3 2026 Results, Raises Full-Year Guidance
HAE
Earnings
Guidance Update
Product Launch
- HAE delivered a strong Q3 2026 with revenue of $339 million and adjusted earnings per share of $1.31, leading to a raise in full-year revenue, earnings, and free cash flow guidance. Year-to-date, adjusted operating margin expanded 200 basis points to 25.7%.
- Growth was driven by NexSys and TEG, which delivered outsized growth, and a strong plasma business benefiting from share gains and double-digit collection volume growth.
- While interventional technology revenue declined 12% in Q3, the company expects this segment to return to growth in FY 2027, supported by the anticipated MVP XL label expansion and the US launch of PerQseal Elite from the Vivisure acquisition.
- The company's capital allocation priorities include organic growth investments, debt reduction, and opportunistic share buybacks.
5 hours ago
Haemonetics Reports Q3 Fiscal 2026 Results and Raises Full-Year Guidance
HAE
Earnings
Guidance Update
- Haemonetics Corporation reported Q3 fiscal 2026 revenue of $339 million, a 2.7% decrease year-over-year, with adjusted earnings per diluted share of $1.31. Year-to-date fiscal 2026 revenue was $988 million, down 4.1%, and adjusted earnings per diluted share was $3.67.
- The company raised its fiscal 2026 guidance for adjusted earnings per diluted share to $4.90 – $5.00 (previously $4.80 – $5.00) and for free cash flow to $200 million – $220 million (previously $170 million – $210 million).
- Gross margin improved to 59.7% in Q3 fiscal 2026 (from 55.5% in Q3 fiscal 2025) due to higher margin offerings and product innovation. Organic ex-CSL revenue grew 7.5% in Q3 fiscal 2026, primarily driven by Plasma and Blood Center businesses.
8 hours ago
Haemonetics Reports Q3 Fiscal 2026 Results and Updates Full-Year Guidance
HAE
Earnings
Guidance Update
M&A
- Haemonetics (HAE) reported Q3 Fiscal 2026 adjusted EPS of $1.31, a 10% increase year-over-year, with an adjusted operating margin of 26.3%.
- The company achieved 8% organic ex-CSL revenue growth in Q3 Fiscal 2026, contributing to total net revenues of $339.0 million.
- Cash generation was strong, with free cash flow increasing 151% year-over-year to $94 million in Q3 Fiscal 2026, and a free cash flow to adjusted net income conversion ratio of 121%.
- Haemonetics updated its full-year Fiscal 2026 guidance, projecting adjusted EPS between $4.90 and $5.00 and free cash flow between $200 million and $220 million.
- Subsequent to quarter-end, the company acquired Vivasure Medical in January 2026 and bought back approximately 360,000 shares of HAE common stock.
8 hours ago
Haemonetics Highlights Strong LRP Performance and Strategic Growth Drivers at J.P. Morgan Conference
HAE
Guidance Update
M&A
Share Buyback
- Haemonetics expects to achieve an 8% total revenue compound annual growth rate and 770 basis points of adjusted operating margin expansion over its four-year Long-Range Plan (FY22-FY26), with adjusted EPS projected to compound at approximately 17%.
- The company has transformed its portfolio, with 85% of FY26 revenue now coming from core high-growth, high-margin businesses, significantly up from 30% in FY22.
- Haemonetics maintains leadership positions in its three core platforms: plasma apheresis (over 50% global market share), viscoelastic testing (TEG, 45% market share), and vascular closure.
- The company recently acquired Vivasure for approximately $60 million to expand into the $300 million large bore closure market, with the PerQseal Elite product currently under FDA review for a planned FY27 launch.
- Capital allocation priorities include organic growth, opportunistic share buybacks ($225 million in the past year), and debt repayment for a $300 million convertible debt maturity in March. Future operating margin expansion is projected at 50-100 basis points annually.
Jan 13, 2026, 3:30 PM
Haemonetics Reports FY25 Performance, Issues FY26 Guidance, and Details Vivasure Acquisition
HAE
Guidance Update
M&A
Earnings
- Haemonetics reported FY25 revenue of $1.36 billion , adjusted EPS of $4.57 , and an adjusted operating margin of 24.0%.
- The company issued FY26 guidance, projecting total reported revenue growth of (1-4%) (or organic, ex-CSL revenue growth of 7-10% ), adjusted EPS between $4.80 and $5.00 , and an adjusted operating margin of 26-27%.
- Strategic growth is driven by its Plasma business, with a ~$1 billion Serviceable Addressable Market (SAM) and ~50% global share , and Interventional Technologies, including the Electrophysiology market with a ~$600 million SAM and ~40% US share.
- Haemonetics acquired Vivasure for up to €185 million , which is expected to unlock a $300 million Total Addressable Market (TAM) and strengthen its vascular closure leadership.
- The business model features 94% recurring revenue and a capital allocation strategy that includes ~$515 million (40%) for M&A out of $1.3 billion total.
Jan 13, 2026, 3:30 PM
Haemonetics Highlights Strong LRP Performance and Strategic Growth Initiatives
HAE
M&A
Share Buyback
Guidance Update
- Haemonetics (HAE) is nearing the completion of its FY22-FY26 Long-Range Plan, expecting an 8% total revenue compound annual growth rate and 770 basis points of adjusted operating margin expansion at the midpoint of its current guidance. This performance is attributed to a portfolio shift, with 85% of FY26 revenue now derived from high-growth, high-margin businesses, up from 30% in FY22.
- The company recently acquired Vivasure for approximately $60 million to expand its vascular closure portfolio into the large bore segment, with the PerQseal Elite product currently under FDA review for a planned FY27 launch.
- Capital allocation priorities include organic growth, M&A (currently paused for IVD improvements), and shareholder returns, with $225 million in share buybacks in the past year and a focus on addressing a $300 million convertible debt maturity by the end of March.
- The plasma franchise, a global leader with over 50% market share and 80% share in the U.S. DMS market, is experiencing significant growth from share gains, price premiums, and normalizing collection volumes, providing a durable source of earnings and free cash flow.
Jan 13, 2026, 3:30 PM
Haemonetics discusses strategic growth and financial performance at J.P. Morgan Healthcare Conference
HAE
M&A
Guidance Update
New Projects/Investments
- Haemonetics reported strong progress on its FY22-FY26 Long-Range Plan, with an expected 8% total revenue compound annual growth rate (13% organic) and 770 basis points of adjusted operating margin expansion at the midpoint of current guidance.
- The company has successfully transformed its portfolio, with 85% of FY26 revenue now derived from core high-growth, high-margin businesses, up from 30% in FY22.
- Haemonetics recently acquired Vivasure for approximately $60 million, expanding its vascular closure offering into the large bore segment, which adds an estimated $300 million addressable market.
- Capital allocation priorities include organic growth, opportunistic share buybacks ($225 million in the past year), and addressing a $300 million convertible debt maturity in March.
- Management expects continued operating margin expansion of 50-100 basis points in future years, driven by operating leverage.
Jan 13, 2026, 3:30 PM
Haemonetics acquires Vivasure, Orchestra BioMed to receive up to $21 million in proceeds
HAE
M&A
New Projects/Investments
- Haemonetics Corporation completed the acquisition of Vivasure Medical Limited on January 9, 2026.
- Orchestra BioMed Holdings, Inc., a strategic holding of Vivasure, expects to receive up to $21 million in cash proceeds from this acquisition.
- Of these proceeds, $11 million is anticipated in 2026, including an approximately $5 million upfront payment and an approximately $6 million first milestone payment.
- The remainder of the proceeds will be received in future revenue earnouts based on the achievement of certain milestones.
Jan 12, 2026, 2:00 PM
Quarterly earnings call transcripts for HAEMONETICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more